Pharma provides upgrade on response to APF530 Complete Response Letter A.P. Pharma, Inc. , a specialty pharmaceutical firm, today provided an update on its progress toward responding to the Complete Response Letter for APF530 that the Company received from the U.S. Food and Drug Administration in March 2010. The Company also announced that it has met with the NASDAQ Listing and Qualifications Panel and is currently awaiting its decision concerning A.P. Pharma’s eligibility for continuing listing. ‘A.P. Pharma’s management group has focused its attempts on addressing the issues contained in the APF530 Complete Response Letter and we’ve arranged Type B meetings with the FDA for later this one fourth,’ said John Whelan, A.P.This profession is filled with people who make an extremely tangible effect on the standard of life of individuals each day, Dockins said. Our fresh Foundation will be devoted to making sure that those qualities of assistance, excellence and caring continue on in new generations of professionals. Our attempts will be aimed toward deepening the understanding, expertise and skills of everyone in the profession, she said, and in addition toward the long-range objective of raising public knowing of the importance of proper nourishment and foodservice administration in achieving good health. The Foundation’s longstanding scholarship programs will continue, she stated, but they shall be augmented with a new focus on fundraising.